Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL5 | P05113 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051661 | 0.73 | CYP1A2 (0.56) | IL5CYP2A6CYP1A2CCR1CCR5 | |
| SCHEMBL19296273 | 0.73 | OGA (0.31) | — | |
| SCHEMBL22065919 | 0.72 | CLK1 (0.37) | PARP1ACHEDAO | |
| SCHEMBL23592132 | 0.71 | STAT3 (0.43) | IL5CYP2A6CYP1A2CCR1CCR5 | |
| SCHEMBL22026782 | 0.70 | IL5 (0.57) | IL5CYP2A6CYP1A2PARP1CCR1 | |
| SCHEMBL31121809 | 0.70 | IL5 (0.57) | IL5CYP2A6CYP1A2PARP1CCR1 | |
| SCHEMBL8274136 | 0.69 | IMPDH2 (0.39) | CYP1A2PARP1ACHE | |
| SCHEMBL22026763 | 0.68 | IL5 (0.42) | IL5NPC1ACHE | |
| SCHEMBL29767811 | 0.68 | IL5 (0.42) | IL5NPC1ACHE | |
| SCHEMBL8276161 | 0.68 | CYP2A6 (0.34) | CYP2A6PARP1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179370-A1 | TREATMENT OF EPILEPSY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179370-A1 | TREATMENT OF EPILEPSY | GABARAPL2, HDAC2, GABRB2 | IL5 3493/4885CYP2A6 177/4885CYP1A2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.